Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This Phase 2 protocol is designed to compare two dose levels of laninamivir octanoate versus
placebo. The objectives are to obtain safety and efficacy in adults aged 18 to 64 years who
present to clinic with symptomatic presumptive influenza A or B infection.